{"prompt": "['1.0 TRIAL SUMMARY', '6', '2.0 BACKGROUND & RATIONAL', '6', '2.1 Unmet medical need and trial rational', '6', '2.1.1 Unmet medical need', '6', '2.1.2 Rational of the trial', '7', '2.2 Pharmaceutical and Therapeutic Background', '8', '2.2.1 Avelumab', '8', '2.2.1.1 Pre-clinical Studies', '9', '2.2.1.2 Phase I study', '9', '2.2.1.3 Ongoing Clinical Trials', '10', '2.3 Information on Other Trial-Related Therapy', '10', '2.3.1 Cyclophosphamide', '10', '2.3.1.1 Metronomic cyclophosphamide', '11', '2.3.2 Radiotherapy', '13', '2.4 Rational for dose selection in the present trial', '15', '2.5 Risk/Benefit Profile', '15', '3.0 STUDY OBJECTIVES', '16', '3.1 Primary study objectives', '16', '3.2 Secondary study objectives', '17', '4.0 STUDY DESIGN', '17', '4.1 Treatment', '17', '4.2 Trial Diagram', '18', '5.0 RATIONALE FOR THE TRIAL AND SELECTED SUBJECT POPULATION', '19', '5.1 Inclusion criteria', '19', '5.2 Exclusion criteria', '20', '6.0 PROTOCOL PROCEDURES', '22', '6.1 Drug Administration', '22', '6.2 Study procedure and Safety Assessment', '23', '6.2.1 Before treatment', '23', '6.2.2 Informed Consent Procedure', '24', '6.2.2.1 Protection of childbearing women and/or of the partner', '24', '6.2.3 Before each course', '25', '6.2.4 Every 8 weeks', '25', '6.2.5 Every 12 weeks until progression or general condition deterioration', '25', '6.2.6 Off-protocol evaluation', '25', 'CONFRONT Study v. 1.1 del 07/05/2018 - Study Protocol', '3']['6.2.7 Toxicity-related dose adjustment', '26', '6.2.8 Treatment modification for symptoms of infusion-related reactions', '28', '6.2.9 Management of immune-mediated adverse reaction', '29', '6.3 Safety Reporting', '38', '6.4 Sample collection, handling, shipping and analysis', '38', '7.0 STUDY ENDPOINTS', '39', '7.1 Primary endpoints', '39', '7.2 Secondary endpoints', '39', '8.0 STATISTICAL CONSIDERATION', '39', '8.1 Hypothesis', '39', '8.2 Statistical considerations, study design and sample size', '40', '8.2.1 Preliminary considerations', '40', '8.2.2 Statistical considerations', '40', '8.2.3 Study design and sample size', '40', '8.2.3.1 Phase I study', '41', '8.2.3.2 Phase II study', '41', '8.3 Response evaluation', '41', '8.4 Study duration', '42', '9.0 FEASIBILITY OF ENROLLING PROPOSED POPULATION, INCLUDING', 'PROJECTIONS', '42', '10.0 QUALITY ASSURANCE AND TRIAL MONITORING', '42', '10.1 Monitoring of the trial', '42', '10.1.1 Steering Committee', '42', '10.1.2 Independent Data Monitoring Committee (IDMC)', '43', '10.1.2.1 Composition of the IDMC', '43', '10.1.2.2 Responsabilities of the IDMC', '43', '10.2 Quality Assurance', '44', '10.2.1 Data Collection', '44', '10.2.2 Data Protection', '44', '10.2.3 Monitoring', '44', '10.2.4 Handling of missing data', '44', '10.2.5 Audits', '45', '11.0 TRANSLATIONAL STUDY', '45', '11.1 Translational Objective', '45', 'CONFRONT Study v. 1.1 del 07/05/2018 - Study Protocol', '4']\n\n###\n\n", "completion": "END"}